Clinical characteristics and patterns and predictors of response to therapy in collagenous and lymphocytic colitis. (November 2015)

• Record Type: Journal Article
• Authors: Colussi, Dora; Salari, Behzad; Stewart, Kathleen O.; Lauwers, Gregory Y.; Richter, James R.; Chan, Andrew T.; Ricciardiello, Luigi; Khalili, Hamed
• Is Part Of: Scandinavian journal of gastroenterology. Volume 50:Number 11(2015)
• Page Start: 1382
• Page End: 1388
• Publication Date: 2015-11
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• Languages: English
• ISSNs: 0036-5521

Abstract

<abstract> <title>Abstract</title> <p> <bold> <italic>Background.</italic> </bold> Collagenous colitis (CC) and lymphocytic colitis (LC) are chronic inflammatory disorders of the colon. There is a paucity of data on differences in etiology, natural history, and treatment response between CC and LC. <bold><italic>Methods.</italic></bold> Between 2002 and 2013, we identified new diagnoses of CC and LC using the Research Patient Data Registry in a tertiary referral center. We used chi square or Fischer's exact test and Wilcoxon rank-sum tests to compare the differences in clinical characteristics, treatment types, and response rates between LC and CC. <bold><italic>Results: </italic></bold> Through 2013, we confirmed 131 patients with a new diagnosis of microscopic colitis (MC) (55 LC, 76 CC). Compared to cases of LC, patients with a diagnosis of CC were more likely to be women (86% vs. 69%, <italic>p</italic> = 0.03), have elevated erythrocyte sedimentation rate (mean 28 vs. 13 mm/h, <italic>p</italic> = 0.04), and less likely to be diabetic (5% vs. 18%, <italic>p</italic> = 0.02). Budesonide was the most effective treatment for both CC and LC (94% and 80%, respectively). However, there were no statistically significant differences in response to various treatments according to the type of MC (all <italic>p</italic> > 0.10). Older age at the time of diagnosis was associated with better response to bismuth subsalicylate (odds ratio: 1.76; 95% confidence interval: 1.21–2.56 for every 5-year increase) for both CC and LC. <bold><italic>Conclusion.</italic></bold> Despite differences in the clinical characteristics, response rates to available treatments appeared to be similar in both LC and CC. Older patients may have a better response to bismuth subsalicylate therapy.</p> </abstract>